Company Announcements

Date

Title

STELFONTA® USA Marketing Authorisation Progress

QBiotics announces clinical collaboration with MSD targeting unresectable melanoma

QBiotics doses first Australian patient in Phase I/II clinical trial for head and neck cancer

Pivotal canine field study results published in The Journal of Veterinary Internal Medicine reveal STELFONTA® (tigilanol tiglate) removes 75% of tumours

QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®

QBiotics raises AU$17.76 million from Sophisticated Investors

QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of STELFONTA®

The first in-human Clinical Phase I study of intratumoural tigilanol tiglate has been published in The Lancet's EBioMedicine journal

QBiotics announces first patient dosed in its Phase I/II clinical trial of tigilanol tiglate for head and neck cancer

STELFONTA Progress with European Medicines Authority

Dr Susan Foden joined the Board of QBiotics

Scientific Presentations: Veterinary Cancer Society, Houston, USA

Tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results presented at prestigious international congresses

International Publication - Tigilanol Tiglate Canine Dose Characterisation Study

QBiotics closes successful Share Offer

Positive results announced with first in-human study of tigilanol tiglate in solid tumours

Prospectus approved by ASIC and opening of QBiotics Group capital raise

QBiotics prepares for a new capital raise

Completion of QBiotics USA veterinary anti-cancer trial in USA treating dogs with Mast Cell Tumours

QBiotics signs supply, marketing and distribution agreement with Virbac for canine cancer treatment